Athena Countouriotis - 09 Feb 2022 Form 4 Insider Report for Turning Point Therapeutics, Inc.

Role
President & CEO, Director
Signature
/s/ Paolo Tombesi, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
09 Feb 2022
Net transactions value
-$107,847
Form type
4
Filing time
11 Feb 2022, 17:07:55 UTC
Previous filing
01 Jul 2021
Next filing
31 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TPTX Common Stock Sale $107,847 -2,971 -5.8% $36.30 47,930 09 Feb 2022 Direct F1, F2
transaction TPTX Common Stock Award $0 +62,400 +130% $0.000000 110,330 09 Feb 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TPTX Stock Option (right to buy) Award $0 +224,640 $0.000000 224,640 09 Feb 2022 Common Stock 224,640 $37.68 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to Reporting Person on February 8, 2021.
F2 The Reporting Person acquired 706 shares on June 10, 2021 pursuant to the Issuer's Employee Stock Purchase Plan (the "ESPP").
F3 Represents restricted stock unit award granted under the Issuer's 2019 Equity Plan.
F4 1/48th of the shares vest monthly following February 9, 2022.